Table 1 Patient characteristics
DOAC group | No-drug group | p value | |
|---|---|---|---|
n = 42 (8.0%) | n = 482 (92.0%) | ||
Sex | Male 23, female 19 | Male 234, female 248 | 0.52 |
Age | 82 (65–95) years | 76 (25–106) years | 0.001 |
Indication for ERCP | |||
Malignant biliary stricture | 10 (24.0%) | 108 (22.4%) | 0.848 |
Bile duct stone | 31 (74.0%) | 333 (69.1%) | 0.603 |
Cholecystitis | 1 (2.0%) | 22 (4.6%) | 0.99 |
Acute pancreatitis | 0 | 2 (0.4%) | 0.99 |
Chronic pancreatitis | 0 | 4 (0.8%) | 0.99 |
Others | 0 | 13 (2.7%) | 0.613 |
Underlying disease‡ | |||
Total | 24 (57.0%) | 47 (9.8%) | < 0.001 |
Hemodialysis | 0 | 5 (1.0%) | 0.99 |
Liver cirrhosis | 3 (7.0%) | 6 (1.2%) | 0.029 |
Cardiovascular disease | 13 (31.0%) | 25 (5.1%) | < 0.001 |
Cerebral hemorrhage | 1 (2.0%) | 9 (1.9%) | 0.57 |
Stroke | 13 (31.0%) | 10 (2.1%) | < 0.001 |
Cholangitis | 33 (79.0%) | 314 (65.1%) | 0.09 |
Platelet (µl) | 17.1 (8.0–52.4) | 20.5 (4.5–67.8) | 0.013 |
PT-INR | 1.21 (1.02–1.72) | 1.06 (0.81–2.46) | < 0.001 |
APTT | 35.9 (26.0–62.6) | 29.8 (3.9–75.8) | < 0.001 |
eGFR | 63.5 (15.4–101.5) | ||
Number of patients with eGFR < 60 | 20 (48.0%) | ||
Patients with eGFR < 60 who were receiving a reduced dose of DOAC | 16/20 (80.0%) | ||